Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2011 Dec;121(12):4621-3.
doi: 10.1172/JCI61127. Epub 2011 Nov 21.

A new medical therapy for Cushing disease?

Affiliations
Comment

A new medical therapy for Cushing disease?

Fredric E Wondisford. J Clin Invest. 2011 Dec.

Abstract

Members of the ErbB family of cell surface tyrosine kinase receptors are important targets for cancer treatment because they frequently contribute to the pathogenesis of malignancy. In this issue of the JCI, Fukuoka et al. generate data that suggest that using a tyrosine kinase inhibitor (TKI) against epidermal growth factor receptor (EGFR; also known as ErbB1) may be a novel approach for treating patients with hypercortisolemia due to pituitary corticotroph adenomas (Cushing disease). While surgical resection remains the cornerstone of treatment for individuals with such tumors, this study suggests that TKIs could perhaps be used to reduce tumor size prior to surgery or to treat recurrent disease after surgery.

PubMed Disclaimer

Figures

Figure 1
Figure 1. The hypothalamic-pituitary-adrenal (HPA) axis in healthy controls and patients with Cushing disease.
The normal HPA axis is subject to negative feedback regulation by circulating cortisol levels. Cortisol normally regulates carbohydrate, protein, and lipid metabolism and plays a key role in the immune system. In Cushing disease, a pituitary corticotroph adenoma secreting too much ACTH activates the HPA axis, resulting in defective negative feedback and excessive cortisol production. Patients exhibit central obesity, hypertension, hyperglycemia, osteoporosis, and muscle atrophy.
Figure 2
Figure 2. Proposed function of the EGFR in pituitary corticotrophs.
(A) Relationship between Pomc expression (which encodes a precursor protein that can be cleaved to generate ACTH) and pituitary cell growth mediated by the MAPK pathway. Corticotroph adenomas have aberrant MAPK pathway activation, resulting in pituitary cell growth and increased Pomc expression (4). (B) Use of a TKI reduces corticotroph adenoma growth and Pomc expression, which is mediated by the MAPK signaling pathway.

Comment on

References

    1. Tritos NA, Biller BM, Swearingen B. Management of Cushing disease. Nat Rev Endocrinol. 2011;7(5):279–289. doi: 10.1038/nrendo.2011.12. - DOI - PubMed
    1. Pivonello R, et al. The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab. 2009;94(1):223–230. doi: 10.1210/jc.2008-1533. - DOI - PubMed
    1. Boscaro M, et al. Treatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009;94(1):115–122. doi: 10.1210/jc.2008-1008. - DOI - PubMed
    1. Fukuoka H, et al. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest. 2011;121(12):4712–4721. - PMC - PubMed
    1. Zhang H, et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest. 2007;117(8):2051–2058. doi: 10.1172/JCI32278. - DOI - PMC - PubMed

Publication types

MeSH terms